Trial Profile

A Phase 2 Randomized Double Blind, Placebo-controlled Study on the Safety and Efficacy of Niclosamide in Patients With COVID-19

Status: Withdrawn prior to enrolment

Phase of Trial: Phase II

Latest Information Update: 28 Apr 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Niclosamide (Primary)
Indications COVID 2019 infections; Gastrointestinal disorders
Focus Adverse reactions; Therapeutic Use
Sponsors First Wave Bio; GridAI Technologies

Most Recent Events

16 May 2024 According to an Entero Therapeutics media release, First Wave Biopharma has changed its name to Entero Therapeutics.
04 Feb 2022 Planned initiation date changed from 1 Jun 2021 to 20 Jan 2022.
04 Feb 2022 Status changed from not yet recruiting to withdrawn prior to enrolment.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com